Progesterone
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Progesterone typically declines before estrogen in perimenopause — making it the earliest hormonal signal of reproductive aging. The classic narrative of menopause focuses on estrogen, but progesterone often drops first, beginning in a woman's late 30s. The resulting progesterone-to-estrogen imbalance produces years of symptoms — sleep disruption, anxiety, mood instability, heavier periods — before estrogen levels shift and before conventional menopause workup would typically be triggered.
- Sleep disruption is one of the most important and underappreciated consequences of declining progesterone. Progesterone metabolizes into allopregnanolone, a neurosteroid that activates GABA-A receptors — the same receptor system targeted by benzodiazepines and sleep medications. Low progesterone means less allopregnanolone, which means reduced GABA-A activity, which manifests as difficulty maintaining sleep, more light sleep, and less restorative slow-wave sleep. This mechanism explains why oral micronized progesterone (which reaches the brain and generates allopregnanolone) consistently improves sleep in perimenopausal women in clinical trials.
- Progesterone has direct anti-inflammatory effects independent of its reproductive role. Progesterone downregulates pro-inflammatory cytokines including IL-6 and TNF-α, and upregulates anti-inflammatory pathways. Declining progesterone in perimenopause contributes to the increase in systemic inflammation (the rise in hsCRP and other inflammatory markers) that accelerates during the menopause transition — a mechanistic link between hormonal decline and the increased cardiovascular and metabolic risk seen after menopause.
- Cycle timing is essential for interpreting progesterone in premenopausal women. Progesterone varies 10–100× across the menstrual cycle — a follicular phase draw will show near-zero levels even in a healthy woman with excellent ovarian function. Mid-luteal phase testing (7 days after ovulation) is the only way to meaningfully evaluate progesterone sufficiency. Without cycle day documentation, a progesterone result is essentially uninterpretable.
- Progesterone connects directly to the testosterone synthesis pathway in both sexes. Progesterone → 17-hydroxyprogesterone → androstenedione → testosterone. In men undergoing testosterone optimization, progesterone levels are sometimes monitored because testosterone therapy can suppress the upstream precursor pathway. In women, progesterone's role in adrenal androgen production connects it to energy, libido, and body composition in ways that extend beyond its classic reproductive function.
The First Hormone to Fall: Progesterone and Perimenopause
The standard narrative of menopause — the story most women hear from their doctors and encounter in health media — centers on estrogen. Estrogen falls. Hot flashes happen. You are menopausal.
This framing misses something important: progesterone typically falls first. The perimenopause transition, which can span 7–10 years before the final menstrual period, often begins with a decline in progesterone production while estrogen levels remain relatively intact or even fluctuate higher. The result is a state of relative estrogen dominance — not because estrogen is elevated in absolute terms, but because its usual counterbalance, progesterone, has weakened.
This estrogen-to-progesterone ratio shift produces a recognizable syndrome: worsening sleep quality (particularly sleep maintenance insomnia), increased anxiety and emotional reactivity, heavier and more irregular periods, breast tenderness, and worsening PMS. These symptoms typically begin in a woman's late 30s or early 40s — a decade or more before the classic hot flashes that most women associate with menopause. For many women, this syndrome goes unrecognized and untreated because it precedes the hormone level changes that conventional menopausal workup looks for.
A mid-luteal progesterone test provides objective data at this stage — capturing what is happening in real time rather than waiting for symptoms to escalate or for other hormone levels to shift.
Progesterone Beyond Reproduction: Sleep, Inflammation, and the Brain
The effects of progesterone extend well beyond its reproductive role. Several mechanisms are relevant to longevity:
Neurosteroid production and sleep architecture: Progesterone is converted in the brain to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors — the same receptors targeted by benzodiazepines, barbiturates, and alcohol. Allopregnanolone promotes slow-wave sleep, reduces anxiety, and modulates stress reactivity through this GABA-A mechanism. Declining progesterone in perimenopause directly reduces allopregnanolone production, which mechanistically explains the sleep disruption and anxiety that characterize this transition. Clinical trials of oral micronized progesterone consistently show improvements in sleep onset, sleep maintenance, and subjective sleep quality in perimenopausal women. 1
Anti-inflammatory activity: Progesterone downregulates pro-inflammatory cytokines including IL-6, TNF-α, and nuclear factor kappa B (NF-κB) signaling. The decline in progesterone during perimenopause is one of several hormonal changes that contribute to the measurable increase in systemic inflammation — the rise in hsCRP, IL-6, and other inflammatory markers — that occurs during the menopause transition and contributes to increased cardiovascular and metabolic risk in postmenopausal women.
Neuroprotection: Progesterone and allopregnanolone have neuroprotective properties in animal models and observational human data, including promotion of myelin formation and reduction of neuroinflammation. Whether this translates to meaningful cognitive protection in the context of normal perimenopause is an active area of research, particularly given the epidemiological link between the timing of menopause and dementia risk.
| Phase / Population | Standard Range | Longevity Optimal | Notes |
|---|---|---|---|
| Follicular phase (women) | 0.1–0.9 ng/mL | N/A — pre-ovulation baseline | Testing in follicular phase is uninformative |
| Mid-luteal phase (women) | 1.8–24 ng/mL | > 7–10 ng/mL | Confirms adequate ovulation |
| Postmenopausal (no HRT) | < 0.1 ng/mL | Per clinical protocol if on therapy | Undetectable without therapy |
| Men | 0.2–1.4 ng/mL | 0.5–1.0 ng/mL | Precursor to testosterone and cortisol |
| Range Type | Value (ng/mL) | Notes |
|---|---|---|
| Standard Clinical Range | Follicular phase (women): 0.1–0.9 ng/mL · Luteal phase (women): 1.8–24 ng/mL · Postmenopausal women: < 0.1 ng/mL · Men: 0.2–1.4 ng/mL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Luteal phase (women): > 7–10 ng/mL (confirms adequate ovulation) · Postmenopausal women on bioidentical progesterone: per protocol · Men: 0.5–1.0 ng/mL |
Associated with reduced all-cause mortality and extended healthspan.
Progesterone interpretation requires knowing where a woman is in her menstrual cycle — a mid-luteal phase draw (approximately 7 days after ovulation, or day 21 of a 28-day cycle) is standard for evaluating progesterone adequacy. A mid-luteal value below 7 ng/mL suggests suboptimal ovulation or luteal phase deficiency even if technically within the broad standard range. Postmenopausal women not on hormone therapy will have essentially undetectable progesterone. For women in perimenopause or on bioidentical progesterone therapy, target levels depend on the specific formulation, route of administration, and clinical context. Cycle day should always be recorded when drawing progesterone.
|
Already have your results? See what your Progesterone and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
When is the right time to test progesterone?
For premenopausal women, progesterone must be tested in the mid-luteal phase — approximately 7 days after ovulation — to reflect the peak of progesterone production that occurs after a successful ovulatory event. In a standard 28-day cycle, this corresponds to roughly day 21, which is why this is often called the 'day 21 progesterone.' In women with longer or shorter cycles, timing should be adjusted: if you ovulate on day 18, test around day 25. The simplest approach is to count 7 days forward from a positive LH surge on an ovulation predictor kit. Testing at any other point in the cycle will show very low progesterone even in women with perfectly healthy ovarian function, making the result misleading. For postmenopausal women, timing matters less (progesterone will be near-undetectable throughout). For women on progesterone therapy, testing timing depends on the specific protocol.
What's the difference between bioidentical progesterone and synthetic progestins?
Bioidentical progesterone (most commonly oral micronized progesterone, sold as Prometrium or compounded) is chemically identical to the progesterone produced by the human body. Synthetic progestins (medroxyprogesterone acetate, norethindrone, levonorgestrel, and others) are structurally modified progesterone analogues developed for oral activity and contraceptive use. The distinction matters clinically for several reasons. Bioidentical progesterone metabolizes to allopregnanolone in the brain, producing the sleep-promoting and anxiolytic effects associated with endogenous progesterone. Most synthetic progestins do not generate allopregnanolone. The landmark WHI trial — which raised concerns about hormone therapy — used synthetic progestins (medroxyprogesterone acetate), not bioidentical progesterone. Subsequent research suggests bioidentical progesterone has a more favorable cardiovascular and breast safety profile than synthetic progestins, though evidence continues to evolve. Standard serum progesterone assays do not measure most synthetic progestins — so a woman on synthetic progestin therapy will show near-zero progesterone on a standard blood test.
Can men benefit from monitoring progesterone?
Men produce progesterone in small quantities from the adrenal glands and testes, and progesterone serves as a direct precursor to testosterone, cortisol, and aldosterone in the steroidogenesis pathway. For men undergoing testosterone optimization therapy — particularly testosterone replacement therapy — some clinicians monitor progesterone because exogenous testosterone can suppress the upstream synthesis pathway. Progesterone also converts to allopregnanolone in the male brain, contributing to sleep quality and anxiolysis. Whether progesterone supplementation in men with low-normal levels produces meaningful clinical benefit is not well-established in controlled trials. For most men not undergoing hormonal optimization, progesterone is not a priority monitoring target — free and total testosterone, SHBG, and estradiol are more directly actionable.
What are the signs that progesterone may be low even before testing?
The classic symptoms of progesterone deficiency in perimenopausal women cluster around three domains: sleep, mood, and menstrual cycle changes. Sleep symptoms include difficulty staying asleep (sleep maintenance insomnia, particularly waking between 2–4 AM), lighter sleep, and feeling unrested despite adequate hours. Mood symptoms include increased anxiety, irritability, and reduced stress resilience — particularly in the two weeks before the period. Cycle changes include heavier periods, shorter cycles (cycle length often shortens as progesterone drops in perimenopause), more pronounced PMS, and breast tenderness. Many women experience these symptoms for years before they connect them to progesterone, attributing them instead to stress, lifestyle, or aging. Testing confirms what the symptom pattern suggests.